Principles of radiation therapy in low-resource and well-developed settings, with particular reference to cervical cancer  by Shrivastava, Shyam Kishore et al.
International Journal of Gynecology and Obstetrics 131 (2015) S153–S158
Contents lists available at ScienceDirect
International Journal of Gynecology and Obstetrics
j ourna l homepage: www.e lsev ie r .com/ locate / i jgoFIGO CANCER REPORT 2015Principles of radiation therapy in low-resource and well-developed
settings, with particular reference to cervical cancerShyam Kishore Shrivastava a, Umesh Mahantshetty a, Kailash Narayan b
a Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
b Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Center, Melbourne, Australia1. Introduction
Gynecological cancers are common in low-resource countries. Cervi-
cal cancer is one of the leading cancers inwomen in India and the fourth
most common cancer in women globally. Surgery with or without ra-
diotherapy is commonly used to treat uterine, vulvovaginal, and early
cervical cancer. Radiotherapy plays an important role in the manage-
ment of cervical cancer, where it is routinely used in radical/curative,
adjuvant, and palliative settings [1,2].
2. Radiation treatment and dose–response relationships
The aim of radiation therapy is to achieve loco-regional control of
cancer while preserving normal tissue functions. Solid tumors have a
variable fraction of clonogenic cells that proliferate like any other nor-
mal tissues in the body. All clonogenic tumor cells must be eradicated
to achieve a cure. To improve the chances of cure, radiation doses may
have to be increased in proportion to the clonogens found in the
tumor. An increased radiation dose may also increase toxic and/or
acute reactions. The increased acute toxicity may be acceptable, provid-
ed it healswithout any deleterious effects on the quality of life in surviv-
ing patients. Late radiation effects from pelvic radiotherapy may result
from damage to the rectosigmoid colon, bladder, small bowel, pelvic
and femoral bone, and bone marrow. The long-term effects of radiation
in these tissues can be minimized by using shrinking radiation ﬁelds,
appropriate shielding and, where possible, conformal radiation tech-
niques giving differential doses to subclinical disease and gross disease
while sparing surrounding non tumor-containing normal tissues.
2.1. Radiation tolerance doses
The tolerance of the cervix and uterus to radiation is usually more
than 200 Gy. With these doses, the rate of necrosis is less than 1%. The
upper vagina and distal vaginal mucosa can be treated up to140 Gy
and 100Gy, respectively. Threshold doses reported for vesicovaginal ﬁs-
tula and rectovaginal ﬁstula are 150 Gy and 80–90 Gy, respectively.
However, these ﬁstulas can occur at much lower doses when the blad-
der base or rectovaginal septum has been grossly inﬁltrated by tumor.
The radiation-induced adverse effects and their manifestations depend
on the type of tissues receiving radiation. Early responding tissues
such as the skin and intestinal mucosa have a high cell turnover andhttp://dx.doi.org/10.1016/j.ijgo.2015.06.013
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).they express radiation injury at about 2–3 weeks following radiothera-
py. Late responding tissues such as spinal cord, rectal wall, bladder, and
kidneys have a slow cell turnover. Radiation injury in these tissues is
expressed in months or years after radiotherapy, as the radiated cell
population slowly enters the active cell cycle phase. In summary, the ra-
diation tolerance is relatively high for the cervix and vagina and low for
adjacent organs.
3. Radiation therapy in cervical cancer
3.1. Radical radiation therapy for cervical cancer
The standard of care for cervical cancers FIGO Stage Ib2 − IIIb is
radical radiation therapy with or without concomitant cisplatin chemo-
therapy. Radical radiation therapy for cervical cancer consists of a combi-
nation of external beam radiotherapy (EBRT) to the pelvis covering the
uterus, cervix, parametria, and pelvic nodes. This is followed by brachy-
therapy to the primary tumor. The aim is to deliver a dose, equivalent
to 80–85 Gy EQD2 (equivalent dose in 2 Gy per fraction) to point A.
The planned radical radiation/concomitant chemoradiation should be
completed within 8 weeks. Prolonging overall treatment time results in
poorer outcomes [3].
3.1.1. External radiation details
Using conventional fractionation, a dose of 40–50.4 Gy in 1.8 or 2 Gy
fractions over a period of 4–6weeks is recommended. Anterior-posterior
(AP-PA) portals or a four-ﬁeld box arrangement can be used. Shielding
corners of radiation ﬁelds helps in reducing the dose to the rectum, blad-
der, and small bowel, thereby reducing the toxicities.
3.1.2. Radiation planning
Either conventional ﬂuoroscopy-guided or computerized tomogra-
phy (CT)-based planning can be used for EBRT. CT-based planning is in-
creasingly used because of the wider availability of CT simulators in
many centers throughout the world. Fluoroscopy-guided conventional
planning is usually performed with the patient in the supine position.
Where a belly board is available, patients can be planned and treated
in the prone position. This helps to push the small bowel loops out of
the pelvis into the abdomen. Under ﬂuoroscopy guidance, bony land-
marks are used to mark the portals. For the AP-PA two-ﬁeld technique,
the upper border of the pelvic treatment portal is located at the L4–5 orGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
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midpubis or inferior border of the obturator foramina or to a line
2–3 cm below the lowest vaginal disease level. Radio-opaque markers
may be placed in the vaginal cavity to identify the disease on the cervix
or vagina. The ﬁelds may be extended superiorly if microscopic or gross
metastatic disease is suspected in para-aortic nodes. The lateral borders
of the pelvic ﬁeld are placed at least 1.5–2.0 cm lateral to the pelvic brim
(bony pelvic sidewall). The lateral borders can be increased and corner
shielding reduced in obese patients to compensate for patient move-
ment during treatment.
Using a four-ﬁeld technique results in lower radiation toxicities com-
paredwith two-ﬁeld AP-PA portals. In the four-ﬁeld technique (anterior-
posterior and bilateral portals), the anterior border of the ﬁeld should be
1 cm anterior to the pubis to adequately cover the uterine fundus and the
anterior extent of the external iliac group of nodes with adequate mar-
gins. The posterior border should be at the S3 vertebra to include the
pre-sacral nodes located in front of the ﬁrst and second sacral vertebrae
and uterosacral ligaments. Customized blocks to shield the small bowel
region anterior-superiorly and the lower anorectal region on the lateral
ﬁelds are helpful in reducing late radiation toxicities in these tissues. Ad-
ditionally, inguinal nodes should be included if the disease is extends into
or beyond the lower third of the vagina.3.1.3. CT-based planning
Aplanning CT (slices 3–5mm in thickness) of the abdomen and pelvis
using ﬁducial skin markers with intravenous contrast is commonly used.
Intravenous contrast assists in differentiating between vessels and nodes.
Conformal planning with two ﬁelds AP-PA or a four-ﬁeld box technique
with blocks or multileaf collimators is planned after contouring various
structures and targets individually. Various conformal radiation tech-
niques are used. These include the three-dimensional conformal radiation
technique (3D-CRT), intensity modulated radiation therapy (IMRT) with
or without image guidance (IGRT).3.2. Brachytherapy
The ultimate in dose conformity and dose escalation for primary tu-
mors of the cervix is achieved using brachytherapy. The use of brachy-
therapy results in organ sparing and improved therapeutic outcome in
terms of local control and reduced toxicities. In the recent past, IMRT/
SBRT boost have been tried in place of brachytherapy. The results of
such treatments have been signiﬁcantly inferior [4]. An accurately
placed brachytherapy application delivers high radiation doses to the
cervix, upper vagina, and medial parametria and relatively lower
doses to the rectum and bladder. Historically, brachytherapy was deliv-
ered with low dose rate (LDR) and medium dose rate (MDR) systems.
This is being progressively replaced with fractionated high dose rate
(HDR) systems. Randomized trials and meta-analysis comparing LDR
with HDR brachytherapy in cancer of the uterine cervix have shown
to be equally effective in terms of local control and survival [5,6]. Either
LDR or HDR brachytherapy can be used, taking into account the avail-
ability of equipment and other logistics of treatment delivery. HDR
brachytherapy can be performed as a day procedure in contrast to ap-
proximately 15–20 hours of continuous LDR treatment. LDR treatment
requires an overnight hospital stay as an inpatient. Radiobiological con-
siderations arising fromusingHDR radiationwould require 3–5 applica-
tions of brachytherapy compared with 1–2 applications of LDR. There
are increasing reports of fewer complications and better local control
using HDR and this is becoming the preferred option [6].
Fractionated HDR brachytherapy treatment is started in the ﬁfth
week of external radiation preferably after obtaining optimum primary
tumor shrinkage. A dose of 7 Gy to point A per fraction and 3–5 fractions
depending on the EBRT doses and cumulative doses to the organs at risk
(bladder and rectum) is delivered.3.2.1. Disease outcome with radical radiation alone
For early stage (IB− IIA) cancer, local control rates of 75% anddisease-
free survival of 60%− 62% at 8 years have been reported. The disease out-
come is better for small tumor sizes where both EBRT and brachytherapy
have been used. For advanced disease, the outcome is better for FIGO IIB
(65%− 70% at 8 years) as comparedwith FIGO IIIB (40% at 8 years). Rad-
ical radiation therapywith conventional 2 Gy per fraction and higher total
doseswith intracavitary brachytherapywithout concomitant chemother-
apy improves disease-free survival, which has been reported in a low-
resource country setting [7]. The outcome improves with reﬁnement of
treatment protocols, a multimodality treatment approach, and with im-
proved compliance to planned treatment [7].
3.3. Concurrent chemoradiation with cisplatin chemotherapy
Five randomized Phase III trials of radical radiotherapy alone versus
concurrent cisplatin-based chemotherapy and radiotherapy for the
treatment of cancer of the uterine cervix have shown the superiority of
concurrent chemoradiotherapy [2,8–11]. A further meta-analysis has
shown an absolute beneﬁt in overall survival and progression-free sur-
vival with chemoradiotherapy in patients with Stage IB2 − IVA and
high-risk patients after hysterectomy [12,13]. While these trials vary
somewhat in terms of heterogeneity in data, stage of disease, suboptimal
doses of radiation, nonuniform usage of chemotherapeutic drugs, differ-
ent schedules and doses of cisplatin, they all demonstrated a signiﬁcant
survival beneﬁt for concurrent chemoradiotherapy. The sole exception
was a Canadian trial that did not ﬁnd any survival beneﬁt of concurrent
weekly cisplatin over radiotherapy alone [14]. The major criticism of
the Canadian study was that nearly two-thirds of the patients who re-
ceived chemoradiation had low hemoglobin, which was not corrected
during radiation and this may have had a negative impact on the thera-
peutic outcome [14]. Subsequently, an individual patient data-based
Cochrane meta-analysis suggested an estimated absolute survival bene-
ﬁt of 10% (Stage IA to IIA), 7% (Stage IIB), and 3% (Stage III − IVa) at
5 years. This analysis also showed a trend toward better outcome in pa-
tients receiving adjuvant chemotherapy following concomitant chemo-
radiation, which needs further evaluation [15].
While chemoradiation is regarded as the new standard of care for
womenwith cervical cancer, it is worth remembering that these results
were obtained in a trial setting in women from afﬂuent countries who
had better nutritional or performance status and generally had normal
renal function comparedwith themajority of women from lower socio-
economic countries. Women from low-income countries generally
present with signiﬁcantly more advanced disease, poorer performance
status, and may not tolerate combination therapy as well as women in
better general health. Therefore, radical radiotherapy alone could be
considered for women with doubtful compliance or poor tolerance to
combinedmodality treatment, taking into account comorbid conditions
and social circumstances. Results of a large ongoing, randomized study
of chemoradiotherapy versus radiotherapy from India (NC00193791)
are awaited.
3.4. Management of vaginal vault cancers or local relapse after
primary surgery
Vault cancers in patients undergoing hysterectomy for presumed be-
nign disease or subtotal hysterectomy for invasive cancers and relapse
following primary surgery may be treated either by radical radiation or
pelvic exenteration. Radical irradiation (with orwithout concurrent che-
motherapy) may cure a substantial proportion of patients with isolated
pelvic failure after primary surgery. Radiation doses and volumes should
be tailored to the extent of disease. A dose of 45–50.4 Gy in 1.8–2.0 Gy
fractionation should be delivered tomicroscopic disease followed by fur-
ther boost to the gross tumor volume with brachytherapy or EBRT to a
total dose of 64–66Gy. The EBRT boost dose should be reduced if concur-
rent chemoradiotherapy is used. Use of an appropriate brachytherapy
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or without cisplatin chemotherapy results in a clinical outcome compa-
rable with advanced cervical cancers [16]. Where synchronous pelvic
and distant recurrence is noted following primary radiotherapy for cervi-
cal cancer, a trial of chemotherapy for symptomatic control is indicated.
Cisplatin and sometimes carboplatin with paclitaxel is used. The expect-
edmedian time to progression or death in such patients is 3–7months. It
could be longer if disease is controlled in the radiated ﬁeld and recur-
rence is observed outside the previously treated volume.
3.5. Local recurrence after primary radiotherapy
The only potentially curative treatment of local failure after primary
irradiation is surgery provided the recurrence is limited to the cervix
and uterus. Pelvic exenteration is often required owing to postradiation
pelvic ﬁbrosis or if clear resectionmargins between the bladder and rec-
tum are not possible. Surgical salvage is contraindicated when in addi-
tion to central recurrence there is pelvic sidewall involvement or in
the presence of extrapelvic disease. The triad of unilateral leg edema,
sciatic pain, and ureteral obstruction is indicative of the extension of dis-
ease to the pelvic sidewall and signiﬁes unresectable disease. Salvage
surgery should only be undertaken in centers equipped with facilities
and expertise to manage complex surgery and its complications. The
prognosis of recurrent disease is better for patients with a disease-free
interval of greater than 6 months and with a recurrence 3 cm or less
in diameter located centrally. Following proper selection of patients,
the ﬁve-year survival with pelvic exenteration is in the order of 30%
and in those suitable for hysterectomy it is 60%. Alternately, in a select
group of patients with local recurrence, salvage re-irradiation using
brachytherapy can be offered. The outcome with salvage re-irradiation
is better with a longer disease-free interval and if there are no late
toxicities from prior radiotherapy. This is achieved with higher
brachytherapy doses [17].
3.6. Systemic chemotherapy in Stage IVB or recurrent metastatic disease
Chemotherapy has a palliative role in patients with metastatic or
recurrent cervical cancer. There are a number of chemotherapeutic
agents with activity in metastatic or recurrent cervical cancer. Cis-
platin is the most active cytotoxic agent, with a response rate of
20%–30% and a median survival of 7 months. A combination of pacli-
taxel and carboplatin was superior to cisplatin alone in terms of re-
sponse, progression-free survival, and sustained quality of life but
not overall survival [18]. In another Gynecologic Oncology Group
(GOG) study, the combination of topotecan and cisplatin was superi-
or to cisplatin alone for response, progression-free survival, and
overall survival [19]. Therefore, selected patients with recurrent or
metastatic disease in good general condition could be offered one
of the combination regimens. For others, single agent cisplatin or
carboplatin and best supportive care continue to be appropriate
choices. Many biological agents have been tried in the treatment of
recurrent, persistent, or metastatic cervical cancer. In a recent ran-
domized study, the use of bevacizumab in addition to chemotherapy
(paclitaxel plus carboplatin or topotecan plus paclitaxel) has shown
an improvement in median overall survival of 3.7 months [20].
Distantmetastases should be treatedwith palliative intent using che-
motherapy or radiotherapy or symptomatic and supportive care only.
Local treatment with radiation therapy is indicated to sites of symptom-
atic metastatic disease. The symptoms may arise from skeletal metasta-
ses, enlarged para-aortic or supra-clavicular nodes, or because of other
distant metastases. Occasionally, fully fractionated chemoradiotherapy
to isolated para-aortic nodal metastases can result in long-term survival
and should be attempted. In view of the shortened life expectancy of pa-
tients with metastatic cervical cancer, palliative radiotherapy should be
given using larger fractions over shorter periods than the duration of
conventional radical courses of treatment. Prospective evaluation ofhypofractionated radiotherapy of advanced pelvic cancers was carried
out by the Radiation Therapy Oncology Group. A total dose of 44.40 Gy
was given in 12 fractions over three courses. Each course consisted of 4
fractions (QUAD SHOT) given twice a day over 2 days and repeated
after an interval of 4weeks. The regimenwasmodiﬁed to 14Gy in 4 frac-
tions repeated two or three times, based on the patient’s general condi-
tion, giving a total dose of 42 Gy over 2 months. The moderate acute
effects are usually seen at around 10 days following the fourth fraction
and these usually heal by the time the patient returns for the subsequent
course. This regimen is better tolerated than 42 Gy given in 12 fractions
and given over 5 days a week, which produces higher and longer-lasting
acute effects on normal tissues for a similar tumor response [21].
4. Radiation treatment-related morbidity
Acute complications manifest during treatment, subacute com-
plications occur at 3–6 months, and late effects manifest after
6 months of treatment.
4.1. Conventional radiation therapy with or without
concurrent chemotherapy
During pelvic radiotherapy, most patients experience mild to moder-
ate fatigue and diarrhea, which respond to rest and antidiarrhealmedica-
tions. Somewomen experience bladder irritation. These acute symptoms
are increasedwhen combinedwith concurrent chemotherapy or extend-
edﬁeld radiation. Patients receiving concurrent chemotherapymay addi-
tionally have hematological and nephrotoxicity (cisplatin).
The late sequelae following radiation therapy commonly affect rec-
tal, bladder, and small bowel function. These effects are radiation
dose-dependent and usually become evident on prolonged follow-up.
The reported grade III/IV late toxicities (requiring hospital admission
or intervention) range from 5% to 15%. In patients treated with image-
guided brachytherapy, the incidence of such radiation effects has been
reduced to less than 3% [22].
Late rectal sequelae in the form of chronic tenesmus, telangiectasia
and profuse bleeding, rectal ulceration, and strictures have been report-
ed (5%–8%). These are usually seen during the 18–36-month follow-up
period. The treatment options include steroid enemas, argon plasma co-
agulation, laser, or formalin application to the affected mucosa. Occa-
sionally a diversion colostomy may be required.
Late bladder complications may manifest as hematuria, necrosis,
and rarely vesicovaginal or urethrovaginal ﬁstula. The incidence of
symptomatic grade III/IV late toxicities of the bladder after radical radi-
ation is 4%–8%. When other measures fail, hyperbaric oxygen therapy
(HBOT) may be tried for the treatment of hematuria. The use of HBOT
remains controversial however [23].
Late small bowel sequelae may manifest as chronic enteritis, sub-
acute intestinal obstruction, perforation, and/or strictures. The inci-
dence of symptomatic grade III/IV late toxicities of small bowel
following radical irradiation is 3%–12%. These sequelae are higher in pa-
tients receiving adjuvant radiotherapy after radical surgery especially
with transperitoneal lymphadenectomies. This is due to the cumulative
and additive effects resulting from the combination of twomajor radical
treatment modalities [1].
Most patients treated with radical radiotherapy have telangiectasia
and ﬁbrosis of the vagina, and signiﬁcant vaginal shortening resulting
in decreased sexual satisfaction and painful intercourse. These compli-
cations can be minimized by appropriate counseling and training in
the use of estrogen cream with vaginal cylinders at the time of radio-
therapy. The weekly application of estrogen with a vaginal cylinder
should be continued in all women irrespective of their sexual status.
This is necessary to avoid thinning of vaginal mucosa thereby avoiding
vaginal spotting, whichmay be perceived by patients as a sign of recur-
rent cancer. Regular sexual activity is likely to enable some stretching of
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5. Modern radiation techniques
In the past twodecades there has been rapid progress in radiation de-
livery techniques in parallel to advances in technology and imaging.
Newer EBRT techniques, such as IMRT, image-guided radiation therapy
(IGRT), and PET-CT guided radiation, have been utilized in the treatment
of cervical cancers. At present there is no conclusive evidence to support
their preferential use. These conformal EBRT techniques involve
contouring of the gross and subclinical disease volumes and normal or-
gans/tissues requiring knowledge of the anatomy as seen on sectional
imaging (CT/MR/PET etc.). The radiation target includes gross tumor vol-
ume (GTV), which includes disease involving the cervix and extension to
the parametria, vaginal wall, uterus, and lymph nodes along with their
intervening lymphatics. The clinical target volume (CTV) includes the
entire cervix, uterus, and parametria up to the lateral pelvic wall and
upper 2 cm of the vagina below the lowermost gross involvement. The
planning target volume (PTV) includes appropriate margins over the
CTV. Consensus guidelines for nodal/lymphatic CTV contouring in cervi-
cal cancer have been published [24,25]. It should be remembered that
these terminologies and conventions are adopted throughmutual agree-
ments by various radiation oncology bodies and are not based on any
treatment results detailing dose response or patterns of failure studies.
Certainly, the contouring of normal tissue is important, as the conformal
mode of EBRT such as IMRT can achieve optimal sparing of normal tis-
sues without compromising the doses to target. However, the day-to-
day organmotion during the course of radiotherapy remains problemat-
ic. Speciﬁc normal tissues contoured are bladder, rectum, sigmoid, small
and large bowel, and bone marrow [22,26,27]. The potential advantages
of using newer EBRT techniques are as follows:
• Limiting doses to normal tissues: This factor is of paramount impor-
tance and is going to be increasingly relevant in the future with the
practice of increasing doses to target volume [22,26–28].
• Dose escalation to the gross disease volume (primary and nodes) is
theoretically an important application of IMRT to any site. For cervical
cancer, brachytherapy excludes most of such need at the primary
tumor site. However, in locally advanced stages with inappropriate
geometry and size of residual disease not suited for brachytherapy,
IMRT could be used [29,30].
• Concomitant boost application to special target regions can be
achieved using IMRT. These regions may include pelvic or para-
aortic lymph nodes or the lateral one-third of the parametrium [22].
• Radical treatments for para-aortic lymph nodes: Although FIGO stag-
ing does not change with identiﬁcation of para-aortic lymph nodes
identiﬁed in imaging alone, the treatment should. Recently, several
authors have prescribed doses of 60–66 Gy with concurrent chemo-
therapy and have demonstrated good local control and acceptable
toxicities [28,31,32]. However, the effect of such dose escalation on
long-term survival remains to be seen.
6. Advances in brachytherapy for cervical cancer
Historically, the brachytherapy systems formulated by theManches-
ter, Paris, and Stockholm groups were based on clinical experience.
These groups managed to deliver curative doses to the cervical tumor
in the absence of treatment planning systems. With the development
of various manuals, after-loaded applicators, and radium substitutes
such as Cs137, Co60, and Ir192, brachytherapy became safe and widely
available. High-dose-rate remote after-loading and advances in treat-
ment planning systems have ensured well-deﬁned protocols and
methods for brachytherapy dose analysis. Up until now, brachytherapy
was based on implant geometry (applicator and point-based) andfounded on theoretical concepts. Such a two-dimensional (2D) system
using orthogonal radiographs had major limitations. It lacked the infor-
mation on the tumor volumes and organs at risk. Conventionally, point
doses are calculated for the rectum and bladder according to Interna-
tional CommissiononRadiationUnits andMeasurements (ICRU) Report
38 recommendations [33]. The ICRU dose points do not represent the
dose received by the entire volume of the organs, and therefore the
doses to the organs at risk are not accurately known. This is evident
from the lack of signiﬁcant correlation between the point doses and in-
cidence of toxicities, especially bladder and small bowel. In addition, the
extent of residual tumor cannot be seen in the radiographs. The position
of the applicator cannot be accurately assessed either within the uterus
or in relation to the surrounding tissues. Hence the dose gradient across
the tumor or the surrounding bowel cannot be ascertained.
Over the last two decades, various imagingmodalities such as ultra-
sound, CT,MRI, and PET have been explored in an effort to delineate the
tumor volume to be targeted by EBRT and brachytherapy. Among the
imagingmodalities, MRI is becoming increasingly popular for diagnosis
and treatment planning for EBRT and brachytherapy. Image-guided
brachytherapy (IGBT) has been possible mainly because of MRI, where
it is possible to image the residual tumor and normal tissues with the
brachytherapy applicator in treatment position. The Group Européen
de Curiethérapie and the European Society for Therapeutic Radiology
and Oncology (GEC-ESTRO) published guidelines for reporting and
practice of IGBT, including the concept of target, dose volume parame-
ters, MR imaging protocols and quality assurance (GEC-ESTRO I-IV rec-
ommendations) [34–37]. These have been widely accepted. According
to these recommendations, the target includes the gross tumor volume
seen asT2 bright areas in the cervix; the high-risk clinical target volume
(HR-CTV) consisting of the entire cervix and presumed disease exten-
sion at the time of brachytherapy (based on clinical and treatment plan-
ning MR image); and the intermediate-risk volume (IR-CTV), up to a
5− 15-mm margin around HR-CTV to encompass the pre-treatment
disease at diagnosis [34]. GEC-ESTRO also recommends starting with
the standard method of dose prescription, either point A or the 60 Gy
reference volume, and then adjusting the loading pattern and dwell
times to ensure comprehensive target (HR-CTV) coverage while
limiting the dose to the organ at risk. Various dose volume parameters
related to target (D90, D100, D98, and V100) and organs at risk
(D0.1 cc, D1cc, D2cc) have been recommended [35]. There are no dose
volume constraints recommended. The dose–response relationships
for various targets and constraints for organs at risk are evolving at
present (ongoing studies, Retro-EMBRACE and EMBRACE studies).
7. Current status of image-guided brachytherapy
A large series published from the Vienna group has reported the
clinical outcome of 156 patients treated with MR image-guided
adaptive brachytherapy combined with 3D conformal EBRT with or
without chemotherapy [38]. The results are promising, with excel-
lent local control rates of 95% at 3 years in limited/favorable (Stage
IB/IIB) groups and 85% in large/poor response (Stage IIB/III/IV)
groups with acceptable treatment-related morbidity rates. Com-
pared with their historical series, there is a relative reduction in pel-
vic recurrence by 65%–70% and a reduction in major morbidity.
Similar mono-institutional series form other centers have been re-
ported [39,40]. MR IGBT is being evaluated further in an ongoing
multicenter study involving several institutions in Europe, the USA,
and Asia (EMBRACE and Retro-EMBRACE).
However, the use of MR imaging for fractionated brachytherapy plan-
ning is not routinely practiced owing to the availability of MRI in radio-
therapy set-ups, economical viability, etc. The use of alternate imaging
modalities such as CT scan, ultrasonography (transabdominal and
transrectal) for IGBT is being evaluated currently with promising results.
For low-income and resource-limited countries where cervical can-
cer is a major health problem, use of a simple, cost-effective imaging
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optimize cervical brachytherapy. Ultrasound-guided intracavitary
brachytherapy for cervical cancer has also been explored [41,42]. The
advantages of the universal availability of ultrasound, its cost-
effectiveness, advances in 3D and real-time ultrasound imaging, and
the small learning curvewouldmake the application of thismodality es-
pecially useful in low-resource countries. Recently, one of the largest
single institutional studies (292 patients) of ultrasound-guided and
MRI veriﬁed dosimetry of conformal brachytherapy of cervical cancer
reported their patterns of failure, late complications, and survival [43].
The conformal brachytherapy has markedly reduced long-term toxic-
ities, usually associated with traditional brachytherapy for cervical can-
cer. However, the effects of such conformal radiotherapy on long-term
survival remain to be established.
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